March 10, 2017 09:36 AM EST
R&D
Pharma

Ar­gos Ther­a­peu­tics slash­es staff in the wake of the lat­est can­cer vac­cine flop

Arsalan Arif

Founder

Two weeks af­ter Ar­gos Ther­a­peu­tics saw its Phase III tri­al of its per­son­al­ized can­cer vac­cine ro­ca­pulden­cel-T end in dis­as­ter, the Durham, NC-based biotech is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Two GSK tri­als with long-act­ing drug in chron­ic rhi­nos­i­nusi­tis hit pri­ma­ry end­points

Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

No­vo Nordisk files 18 law­suits against GLP-1 com­pounders in 44 days

Up­dat­ed: Lund­beck makes $2.6B cash move for Long­board a month af­ter start­ing Phase 3 in Dravet syn­drome

No­var­tis used a PRV to speed Kisqal­i's lat­est in­di­ca­tion, FDA says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times